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Aim: To assess whether the previously developed multivariable risk prediction frame-
work (PRE score) could predict the renal effects observed in the EXSCEL cardiovascu-
lar outcomes trial using short-term changes in cardio-renal risk markers.
Materials and Methods: Changes from baseline to 6 months in HbA1c, systolic blood
pressure (SBP), body mass index (BMI), haemoglobin, total cholesterol, and new
micro- or macroalbuminuria were evaluated. The renal outcomes were defined as a
composite of a sustained 30% or 40% decline in estimated glomerular filtration rate
(eGFR) or end-stage renal disease (ESRD). Relationships between risk markers and
long-term renal outcomes were determined in patients with type 2 diabetes from the
ALTITUDE study using multivariable Cox regression analysis, and then applied to
short-term changes in risk markers observed in EXSCEL to predict the exenatide-
induced impact on renal outcomes.
Results: Compared with placebo, mean HbA1c, BMI, SBP and total cholesterol were
lower at 6 months with exenatide, as was the incidence of new microalbuminuria.
The PRE score predicted a relative risk reduction for the 30% eGFR decline + ESRD
endpoint of 11.3% (HR 0.89; 95% CI 0.83–0.94), compared with 12.7% (HR 0.87;
0.77–0.99) observed risk reduction. For the 40% eGFR decline + ESRD endpoint, the
predicted and observed risk reductions were 11.0% (HR 0.89; 0.82–0.97) and 13.7%
(HR 0.86, 0.72–1.04), respectively.
Conclusions: Integrating short-term risk marker changes into a multivariable risk
score predicted the magnitude of renal risk reduction observed in EXSCEL.
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1 | INTRODUCTION
Recent cardiovascular outcome trials in patients with type 2 dia-
betes (T2D) have characterized the cardiovascular safety of
glucagon-like peptide-1 receptor agonists (GLP-1RAs),1-3 with
some trials also showing cardiovascular protective effects.2,3 The
Exenatide Study of Cardiovascular Event Lowering (EXSCEL,
NCT01144338) assessed the cardiovascular safety of the GLP-
1RA exenatide in a broad range of patients with T2D, with or
without atherosclerotic cardiovascular disease (ASCVD), and con-
firmed that exenatide did not increase cardiovascular risk.1 Sec-
ondary analyses of some of the cardiovascular safety trials with
GLP-1RAs have suggested that this drug class may also delay the
progression of diabetic kidney disease (DKD);4,5 multiple GLP-
1RA trials in T2D have shown a robust effect on new persistent
macroalbuminuria. Additionally, there is some evidence of slowing
eGFR decline, either as a percentage reduction in eGFR or
improvement in eGFR slope in some populations.3,5,6 This benefit
probably results in part from improvement in glycaemic control
but may also be mediated by other effects such as reductions in
blood pressure, body weight, albuminuria, and inhibition of
proinflammatory mediators, although the size of contribution
from each factor is not well understood.7,8
Recognizing the potential contributions of these different pro-
cesses to GLP-1RA-mediated slowing of renal disease progression,
we hypothesized that a multivariate risk score may be able to pre-
dict GLP-1RA-mediated renal effects better than a single risk
marker. We have previously developed and validated such a multi-
variable risk prediction framework (PRE score) to predict longer
term drug impact on renal and/or cardiovascular outcomes.9 The
objective of the PRE score is to predict the effect of a drug on lon-
ger term renal or cardiovascular outcomes based on short-term (eg,
6 month) risk marker changes, as would be measured in, for exam-
ple, a phase 2 trial, to give an estimate of the outcomes in a longer
term outcomes trial in advance of such data being available. The
PRE score can also provide insight into the size of contribution of
different risk factor changes to the observed drug-induced risk
change. The PRE score was developed and validated in trials with
renin-angiotensin-aldosterone-system inhibitors and subsequently
applied to trials with endothelin receptor antagonists and sodium-
glucose co-transporter-2 inhibitors, drugs that also effect multiple
risk factors through different mechanisms.9-11 To date, the PRE
score has not been applied to a GLP-1RA and it is not known
whether it can predict renal outcomes for this class of glucose-
lowering agents.
We performed a post hoc analysis of EXSCEL to determine
the short-term effects of exenatide on multiple cardio-renal risk
markers, and examined whether the PRE score could accurately
predict the longer term impact of a GLP-1RA, exenatide, on the
observed renal disease progression in EXSCEL.
2 | MATERIALS AND METHODS
2.1 | Patient population
EXSCEL included patients with T2D, of whom 73% had prior
ASCVD. Participants were assigned to receive subcutaneous injec-
tions of once-weekly exenatide (EQW) at a dose of 2 mg or
matching placebo, and were followed for a median of 3.2 years. The
EXSCEL design and primary results have been previously published.
1,12 Key inclusion criteria included an HbA1c of 6.5% to 10%, aged
≥18 years, one or fewer severe hypoglycaemia episodes in the past
year, and an estimated glomerular filtration rate (eGFR) ≥30 mL/
min/1.73 m2.
The PRE score was used to predict the effect of exenatide on
renal outcomes in the EXSCEL trial. The PRE score is a flexible
framework that can be customized to any population, drug, and set
of risk markers of interest by fitting the beta coefficients in the
underlying Cox model to the appropriate set of risk markers in a rel-
evant population. For this analysis, the relationships between risk
markers and renal outcomes were established at baseline in a back-
ground population derived from the ALTITUDE trial, a study in
patients with T2D at high cardiovascular and renal risk.13 A sub-
group of patients with urine albumin:creatinine ratio (UACR)
<400 mg/g and eGFR >55 mL/min/1.73m2 was included in the
analysis to calculate risk marker-outcome relationships in a popula-
tion that is representative of patients included in the EXSCEL trial.
The baseline characteristics of the ALTITUDE population are pres-
ented in Table S1.
2.2 | Cardio-renal risk markers
Variables measured in the EXSCEL intention-to-treat population,
and which have previously been identified as risk markers for
progression of renal disease, included: HbA1c, systolic blood
pressure (SBP), UACR, body mass index (BMI), haemoglobin
(Hb) and total cholesterol (TC). Because of a lack of consistently
collected continuous data for UACR in EXSCEL, categorical
information on new micro- or macroalbuminuria was used to
reflect short-term UACR changes. Data on UACR levels in the
ALTITUDE population used were similarly categorized into normo-,
micro- or macroalbuminuria.
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2.3 | Outcome definitions
eGFR was derived from locally measured serum creatinine values
using the Modification of Diet in Renal Disease equation. The renal
outcome was defined as a composite of time to the first sustained
30% decline in eGFR or end stage renal disease (ESRD: chronic dialy-
sis or renal transplantation). A sustained decline was defined as two
consecutive qualifying measurements calculated from site-reported
serum creatinine measurements using the Modification of Diet in
Renal Disease (MDRD) formula. A sustained 30% eGFR decline was
used as a component of the composite outcome because it reflects a
large decline in eGFR in patients with preserved renal function such
as those included in EXSCEL, and has been proposed as an alternative
renal endpoint for drugs without acute eGFR effects such as GLP-
1RAs. 14 We also assessed the effect of exenatide on the composite
of 40% eGFR decline or ESRD because in certain settings this may be
a more robust endpoint than a 30% eGFR decline.15 In the ALTITUDE
subpopulation, the composite renal outcome with 30% eGFR decline
and the outcome with 40% eGFR decline occurred in 292 (17.4%) and
153 (9.1%) patients during a median follow-up of 2.8 years,
respectively.
2.4 | Statistical analysis
The observed drug-induced reduction in risk of the composite renal
outcome was calculated using a Cox proportional hazards model with
exenatide treatment as explanatory variable. Relative risk reductions
were calculated by (1 - hazard ratio) x 100%.
A Cox proportional hazards model was used to estimate the coef-
ficients associated with each risk marker for the first recorded renal
event in the background population derived from the ALTITUDE pla-
cebo arm among subjects with all required covariates measured at
baseline. These coefficients were then applied to the baseline and
6-month cardio-renal risk factor measurements of patients in the
EXSCEL trial to estimate the risk of renal outcomes at both time
points in both the EQW and placebo arms (S tð Þ= Soe
P
βi*xi , where sur-
vival at time t is a function of baseline survival [So], the estimated β
coefficients, and the respective risk marker measurements). These risk
predictions are normalized by the mean predicted risk in the placebo
arm at 6months. Then, the mean difference in the predicted risk in
the exenatide arm, adjusted for the mean difference in the predicted
risk in the placebo arm, represents the PRE score, and reflects an esti-
mation of the expected renal risk reduction conferred by exenatide
treatment. To generate 95% confidence intervals on the predicted risk
reduction, 1000 sets of coefficients were generated from independent
normal distributions based on the estimated regression coefficients
and their standard error from the Cox proportional hazards model.
Before applying the PRE score, here calibrated to the ALTITUDE
trial, multiple imputations were performed on the baseline and
6-month EXSCEL data using the “mice” package in R. Imputation for
numeric covariates was performed by predictive mean matching, a
semiparametric imputation method that replaces missing variables
based on a multivariable regression model.16,17 An imputation
method based on logistic regression was used to impute missing
values of categorical albuminuria. Imputations were performed with
10 iterations, and all metrics included in the PRE score at baseline and
month 6 were used as predictors. Covariate distributions were
checked visually to ensure reasonably imputed values. In the main
analysis, the predictions were generated using all EXSCEL participants
missing one or fewer of the required covariates at baseline and/or
month 6. The percentage of data missing for each risk marker can be
found in the footnote of Table S3.
Mean and standard deviation (SD) are provided for variables with
a normal distribution, whereas medians (25th and 75th percentiles)
are provided for those with a skewed distribution. Categorical vari-
ables are reported as frequencies and percentages. Two-sided P-
values <0.05 indicated statistical significance. All statistical analyses
were conducted with R version 3.0.1 or 3.4.0 (R Project for Statistical
Computing, http://www.r-project.org).
3 | RESULTS
A total of 14 752 patients were randomly assigned to receive placebo
(N = 7396) or EQW (N = 7356) and were included in the EXSCEL
intention-to-treat population. Demographic and clinical characteristics
of these patients were well-balanced between the treatment groups
(Table 1). EXSCEL participants were generally characterized by a low
risk of complications attributable to renal disease. At baseline, 25% of
participants had an eGFR of >90 mL/min/1.73m2, 50% had an eGFR
between 60 and 90 mL/min/1.73m2, and 24% had an eGFR between
30 and 59 mL/min/1.73m2. The prevalence of micro- and
macroalbuminuria was 12.7% and 3.3%, respectively. The
β-coefficients of the PRE score fit to the ALTITUDE subpopulation
with UACR <400 mg/g and eGFR >55 mL/min/1.73m2 are shown in
Table S2.
3.1 | Effects of exenatide on cardio-renal risk
markers
A total of 3395 participants in the placebo group and 3523 in the
exenatide group had ≤1 risk marker missing at baseline or 6 months,
and were included in these analyses after imputation of missing
values. Their baseline characteristics were similar to those of the total
population (Table S3).
Changes in cardio-renal risk markers from baseline to 6 months
after treatment with EQW or placebo are shown in Figure 1. Com-
pared with placebo, greater reductions were seen with EQW in
HbA1c (−0.79%, 95% CI −0.84 to −0.74, P <0.001), BMI (−0.50 kg/
m2, 95% CI −0.57 to −0.43, P <0.001), SBP (−1.7 mmHg, 95% CI −2.5
to −0.9, P <0.001) and TC (−0.14 mmol/L, 95% CI −0.19 to −0.09,
P <0.001). During the first 6 months of placebo treatment, 136 (4.0%)
participants with normoalbuminuria at baseline progressed to
microalbuminuria or macroalbuminuria versus 106 (3.0%) in the EQW
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arm (P for difference 0.03). Progression to microalbuminuria occurred
in 97 (2.9%) of the participants on placebo versus 69 (2.0%) patients
on EQW (P for difference 0.02). Progression to macroalbuminuria
occurred in 39 (1.1%) and 37 (1.0%) of participants in the placebo and
EQW groups, respectively (P for difference 0.79).
3.2 | Predicted longer term effect of EQW on renal
outcomes
The predicted risk change for the composite renal endpoint of ≥30%
eGFR decline or ESRD based on the observed placebo corrected
change in HbA1c alone was −9.9% (95% CI −14.7 to −4.9) with EQW
(Figure 2A). The PRE score with coefficients fit in ALTITUDE
predicted the effect of EQW on the composite renal endpoint in
EXSCEL to be −11.3% (95% CI −16.7 to −5.9). The predicted risk
change for the composite endpoint of ≥40% eGFR decline or ESRD in
EXSCEL was −11.0% (95% CI −18.5 to −3.2) (Figure 2B). For both
endpoints, HbA1c provided the largest contribution to the observed
risk reduction, followed by SBP and Hb.
3.3 | Impact of EQW on renal outcomes
In the overall EXSCEL population, the composite renal outcome of
≥30% eGFR decline or ESRD occurred in 546 (7.4%) participants in
the placebo group compared with 489 (6.7%) in the EQW group
(HR 0.87, 95% CI 0.73 to 0.99, P = 0.03; Figure 3A). A ≥30% eGFR
decline occurred in 533 (8.3%) participants in the placebo group ver-
sus 482 (7.5%) in the EQW group (HR 0.88, 95% CI 0.78 to 1.00,
P = 0.10). The composite renal outcome of ≥40% eGFR decline or
ESRD occurred in 241 (3.3%) participants in the placebo group and
213 (2.9%) in the EQW group during a median follow-up of 2.6 years
(Figure 3B), a relative risk reduction with EQW of 14% (HR 0.86, 95%
CI 0.72 to 1.04; P = 0.12). ESRD was an infrequent event during the
trial, occurring in 39 (0.5%) participants in the placebo group and
25 (0.3%) participants in the EQW group, with an ESRD HR of 0.65
(95% CI 0.39 to 1.08; P = 0.10).
Among the population used for the PRE score analysis with ≤1
cardio-renal risk factor missing (N = 6918), the observed relative risk
reduction of 11.6% for the composite outcome of 30% eGFR decline
and ESRD was consistent with that of the overall population
(HR 0.88; 95% CI 0.74 to 1.05, P = 0.16), although the confidence
intervals were wider, reflecting the smaller number of patients. Simi-
larly, the observed relative risk reduction of 14.2% for the composite
outcome of 40% eGFR decline and ESRD did not differ from that in
the overall population (hazard ratio 0.86; 95% CI 0.66 to
1.12, P = 0.26).
4 | DISCUSSION
In this post hoc analysis of the EXSCEL trial, we showed that EQW
2 mg reduced multiple cardio-renal risk markers after 6 months treat-
ment in a broad population of patients with T2D. Integrating these
short-term changes in multiple risk markers resulted in a predicted
renal risk reduction of 11% when using the PRE score calibrated to
ALTITUDE, which was of a similar magnitude to the relative risk
reduction observed in the trial. These results support further clinical
trials to prospectively assess the renal efficacy of EQW.
Prior studies have suggested that GLP-1RAs may slow renal dis-
ease progression in patients with T2D. A prespecified analysis from
the ELIXA trial reported that patients treated with the short-acting
GLP-1RA lixisenatide showed a smaller increase in albuminuria from
baseline to 108 weeks compared with placebo-treated patients (24%
vs. 34%; P = 0.004).18 No effect was observed on eGFR decline in that
study. In the LEADER and SUSTAIN-6 trials, liraglutide and
semaglutide reduced the composite renal outcome of new onset of
TABLE 1 Baseline characteristics of the placebo and exenatide





Age (years) 61.9 (9.4) 61.8 (9.4)
Female, n (%) 2809 (38) 2794 (38)
Race, n (%)
Caucasian 5621 (76.0) 5554 (75.5)
Black 436 (5.9) 442 (6.0)
Asian 727 (9.8) 725 (9.9)
Other 612 (8.3) 635 (8.6)
HbA1c (%) 8.1 (1.0) 8.1 (1.0)
Systolic BP (mmHg) 135.5 (16.9) 135.4 (16.9)
Diastolic BP (mmHg) 78.0 (10.2) 78.2 (10.3)
UACR (mg/g) 23.8 [13.5, 35.1] 22.9 [11.6, 34.1]
Body mass index (kg/m2) 32.7 (6.4) 32.6 (6.3)
Haemoglobin (g/L) 138.3 (15.8) 138.4 (15.6)
Cholesterol (mmol/L) 4.5 (1.3) 4.5 (1.3)
eGFR (ml/min/1.73m2)a 76.6 (24.0) 77.1 (23.5)
UACR category, n (%)
UACR <30 mg/g 6245 (84.4) 6151 (83.6)
UACR 30–300 mg/g 892 (12.1) 981 (13.3)
UACR >300 mg/g 259 (3.5) 224 (3.0)
eGFRa category, n (%)
eGFR >90 mL/min/1.73m2 1873 (25.4) 1871 (25.5)
eGFR 60–90 mL/min/1.73m2 3683 (50.0) 3732 (50.9)
eGFR 30–59 mL/min/1.73m2 1794 (24.3) 1712 (23.3)
eGFR <30 mL/min/1.73m2 18 (0.2) 17 (0.2)
Abbreviations: BP, blood pressure; eGFR, estimated glomerular filtration
rate; UACR, urine protein:urine creatinine ratio.
Numeric variables are presented as mean (SD) if normally distributed.
UACR is presented as median [IQR]. Categorical variables are presented as
frequency (%).
aCalculated with the Modification of Diet in Renal Disease study
equation (MDRD).
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persistent macroalbuminuria, persistent doubling of serum creatinine
level and ESRD by 22% and 36%, respectively.3,5 These favourable
effects were predominantly driven by reductions in the risk for
macroalbuminuria. The benefit on a clinically meaningful endpoint of
doubling of serum creatinine or ESRD in these trials was less clear,
although slowing of eGFR decline in subjects with moderate-to-
severe CKD was observed in LEADER and AWARD-7,3,5 as well as a
reduction of 40% eGFR decline or ESRD with the higher dose of
dulaglutide (1.5 mg) in AWARD-7, driven by events in participants
with macroalbuminuria at baseline.19 In the REWIND trial, dulaglutide
reduced the risk of a composite endpoint of new onset macro-
albuminuria, sustained 30% eGFR decline or ESRD with the clearest
and statistically significant effect for the development of
macroalbuminuria.6 Although the risks for the 30% eGFR decline
and ESRD components were numerically reduced, they did not
reach statistical significance in REWIND. 6 A sensitivity analysis of
sustained 40% and 50% eGFR declines in REWIND did show a
nominally significant improvement with dulaglutide in the median
5.4 year follow-up in REWIND. 6 In this analysis, we showed for
the first time that treatment with exenatide nominally significantly
lowered the risk of a composite endpoint—30% eGFR decline or
ESRD—that did not include the surrogate albuminuria. Replacing
the 30% eGFR decline by a more robust yet less frequent endpoint
of 40% eGFR decline yielded similar estimates of the treatment
effect size, although it did not reach statistical significance. As
reported elsewhere, a renal composite endpoint of sustained 40%
eGFR drop, ESRD, and new macroalbuminuria was statistically
improved in EXSCEL by exenatide, although only in the adjusted
analysis. 20,21 Given the low frequency of renal outcomes in this
population with preserved eGFR and low UACR at baseline, we did
not analyse outcomes or the predictive ability of the PRE score as a
function of baseline eGFR. Dedicated renal outcome trials with
GLP-1RAs are needed to more definitively assess the ren-
oprotective potential of these compounds; the FLOW renal out-
comes trial for semaglutide is currently ongoing (NCT03819153). 22
While the results here suggest a large contribution of HbA1c to
the improvement in renal outcomes in EXSCEL, treatment with EQW
and other GLP-1RAs has multiple additional effects that are also asso-
ciated with improved renal outcomes. Although the mechanisms
underlying the effects of incretin-based therapies are not completely
understood, there is growing evidence that several nonglycaemic
mechanisms mediate the renoprotective effects of incretin-based
therapies, possibly to a larger extent than observed here in at least
some populations. Firstly, GLP-1RAs have been suggested to enhance
sodium excretion by inhibition of the sodium-hydrogen exchange
3 transporter without altering intraglomerular pressure. 23-25
Enhanced sodium excretion may result in blood pressure and body
weight reductions. Secondly, GLP1-RAs appear to exert direct effects
on the renal vascular endothelium, which may be involved in their
albuminuria-lowering effect and stabilization of renal function decline.
26-28 Moreover, preclinical and clinical studies have suggested that
GLP-1RA therapy may attenuate inflammation and oxidative stress,
thereby reducing renal tissue injury. 29-31 Further research will be
needed to fully elucidate the contributions of these different risk fac-















































8.1 8.1 Baseline value 135.9 135.8 138.2 138.6 4.5 4.5 32.7 32.7 
F IGURE 1 Changes in cardio-renal risk markers from baseline to 6 months in the included population of the EXSCEL trial. Changes are shown
as mean (±95% CI) for the once-weekly exenatide (EQW) at a dose of 2 mg and placebo groups. BMI, body mass index; SBP, systolic blood
pressure
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The longer term effects of EQW on renal outcomes were accu-
rately predicted by the PRE score algorithm. The PRE score has previ-
ously been used to predict the long-term renal effects of renin
angiotensin aldosterone system (RAAS) inhibitors, endothelin receptor
antagonists and sodium-glucose co-transporter-2 inhibitors. 32-34
These results appear to extend to the GLP-1RA exenatide, thereby
extending the applicability of the algorithm. The reduction in HbA1c
appeared to be the driving variable for the observed renal risk reduc-
tion. This contrasts with previous studies where reductions in albu-
minuria were the driving variable for the observed renal risk
reduction. 34-36 Differences in the measurement and registration
between prior trials and the EXSCEL trial (eg, pragmatically collected
data on transition in albuminuria stage in EXSCEL without confirma-
tion via UACR vs. percentage change in UACR in other trials), as well
as the large proportion of patients with low levels of albuminuria in
EXSCEL, may explain this. However, the results here do suggest that a
reasonable prediction of drug effect on renal risk may be plausible
even if only categorical information on UACR is collected, highlighting
the ability to tailor the PRE score construct to risk factors of interest
that were collected in a particular population.
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F IGURE 2 Predicted risk change for the composite renal outcome of ≥30% estimated glomerular filtration rate (eGFR) decline or end-stage
renal disease (ESRD) (A) and for the composite renal outcome of ≥40% eGFR decline or ESRD (B) in the EXSCEL population based on changes in
single risk markers and the integrated effects of all risk markers. Circles indicate point estimates of the percentage mean change in relative risks
with end-stage renal disease compared with placebo, with their 95% confidence intervals. BMI, body mass index; SBP, systolic blood pressure
*Because of a lack of continuous data for albuminuria in the EXSCEL trial, categorical information on new micro- or macroalbuminuria was used
to reflect short-term changes in albuminuria
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What is the applicability of the PRE score in future clinical trials?
Surrogate endpoints based on a single risk marker may not capture
the overall drug effect. Indeed, multiple examples exist where drug
effects on single surrogates insufficiently predict the drug effect on
long-term clinical outcomes. 13,37-39 Apparently, additional drug
effects beyond the single surrogate substantially influenced long-term
outcome. Integrating multiple effects of a drug assists in better long-
term drug efficacy prediction, yet few tools or applications of such
tools exist to date. The PRE score is intended as a flexible framework
for predicting drug effects based on short-term changes in clinical
chemistry variables that have been measured in trials, as opposed to
using a fixed set of biomarkers as many individual risk prediction
scores do. As such, the PRE score can be applied during early clinical
trials and provide information as to whether (or in which patients) the
drug is probable to be effective and may inform power and sample
size calculations. In this analysis, we used 6-month risk markers from
EXSCEL to predict long-term outcomes in the same trial after fitting
the coefficients to a background population in ALTITUDE, as opposed
to the intended future use of predicting outcomes based on earlier
data prior to initiation of the outcomes trial. This is because, as the
first attempt to apply the PRE score construct to the GLP-1RA class,
we were interested in whether, given the true risk marker changes,
the PRE score could predict outcomes. This validity for the GLP-1RA
class must be established before the PRE score is used to prospec-
tively inform the design of an outcomes trial (ie, using phase 2 trial
data to predict the effect of a drug on long-term outcomes in a phase
3 trial). Note that the purpose of the PRE score is not to predict indi-
vidual renal risk, but rather to predict long-term drug efficacy. An
intentional choice to include only modifiable risk factors in the score
captures many drug-induced changes in risk factors. Risk factors not
alterable by drug exposure (eg, age or demographics) do not contrib-
ute to drug efficacy estimation and therefore are not included.
An important feature of the PRE score is that the beta coeffi-
cients can be fit to an independent dataset, collected from a trial
designed to study a different drug, where baseline risk marker levels
and long-term outcomes data are collected. Here, we fit the beta
coefficients to a subpopulation from ALTITUDE, then made predic-
tions in EXSCEL. A new background dataset is not needed for every
drug desired to be studied. However, we selected a background
dataset that includes a similar population to the population of interest,
and in which the relevant risk factors known or thought to be modi-
fied by the drug of interest are measured, to appropriately predict the
drug-induced risk change for our target population.
This analysis has limitations. The analyses were exploratory and
post hoc in nature and therefore the results should be interpreted as
hypothesis generating. The majority of participants in the EXSCEL trial
had only mild to moderate chronic kidney disease, and therefore the
number of ESRD events during the trial was low. Thus, further study
would be required to evaluate the validity of the PRE score in
predicting EQW effects on renal outcomes in more advanced kidney
disease. Determining whether EQW genuinely slows progression of
renal function decline would require a dedicated hard outcome trial in
a population at risk of renal disease progression to capture a sufficient
number of clinically meaningful ESRD events. Furthermore, despite
the use of multiple imputation in participants missing ≤1 of the
required risk marker data at baseline and/or month 6, a small propor-
tion of participants in the EXSCEL trial had complete risk marker data
available. As a result, our predictions are based on a subset of patients
in the EXSCEL trial with most risk marker data available, possibly
inducing bias. Additionally, to keep the PRE score easy to apply and
focused on modifiable risk factors, it does not account for changes in
risk factors not included in the score (eg, changes in medication use),
demographics, or complex interactions between risk factors. To allow
the PRE score to be used when only short-term risk marker changes
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are available, the PRE score estimates drug-induced risk reduction
based on 6-month changes in risk markers; changes occurring on a
longer timescale may be under-represented in the PRE score. Finally,
the high premature discontinuation rate in the EXSCEL trial may have
influenced the observed effect of EQW on renal outcomes, as well as
the observed changes in risk markers upon which the PRE score is
built.
In conclusion, among patients with T2D at cardiovascular risk,
EQW compared with placebo decreased multiple cardio-renal risk
markers and reduced the risk for progression of renal disease. Integra-
tion of the short-term risk marker changes resulted in a predicted risk
reduction of similar magnitude to the actual observed risk reduction
for renal outcomes.
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